Theravance to Present at the 13th Annual Stanford Group Healthcare Conference

SOUTH SAN FRANCISCO, CA, Jan 15 (MARKET WIRE) --
Theravance, Inc. (NASDAQ: THRX) announced today that Michael W. Aguiar,
Theravance's Senior Vice President and Chief Financial Officer, is scheduled to
present at the 13th Annual Stanford Group Healthcare Conference on Thursday,
January 17, 2008, at 1:45 p.m. EST. The conference will be held from January
16-17, 2008 at the Four Seasons Hotel in Washington, D.C.

The presentation will be webcast live and can be reached from Theravance's
web site at
www.theravance.com. Listeners are encouraged to visit the site at least 15
minutes prior to the scheduled presentation to register, download and install
any
necessary audio software.

About Theravance

Theravance is a biopharmaceutical company with a pipeline of internally
discovered
product candidates. Theravance is focused on the discovery, development and
commercialization of small molecule medicines across a number of
therapeutic areas including respiratory disease, bacterial infections and
gastrointestinal motility dysfunction. Of the six programs in development, four
are in late stage -- its telavancin program focusing on treating serious
Gram-positive bacterial infections with Astellas Pharma Inc., the
Gastrointestinal Motility Dysfunction program, the Horizon program (Beyond
Advair
collaboration) with GlaxoSmithKline plc, and TD-1792 for the treatment of
serious
Gram-positive bacterial infections. By leveraging its proprietary insight of
multivalency toward drug discovery focused on validated targets, Theravance is
pursuing a next generation strategy designed to discover superior medicines in
areas
of significant unmet medical need. For more information, please visit the
company's
website at www.theravance.com.

THERAVANCE(R), the Theravance logo, and MEDICINES THAT MAKE A
DIFFERENCE(R)are registered trademarks of Theravance, Inc.

Theravance's presentation at the 13th Annual Stanford Group Healthcare
Conference
will contain certain "forward-looking" statements as that term is defined in
the Private Securities Litigation Reform Act of 1995 regarding, among other
things, statements relating to goals, plans, objectives and future events.
Theravance intends such forward-looking statements to be covered by the safe
harbor
provisions for forward-looking statements contained in Section 21E of the
Exchange Act
and the Private Securities Litigation Reform Act of 1995. Examples of such
statementsinclude statements relating to the goals, timing and expected results
of
clinical and preclinical studies, statements regarding the potential benefits
and
mechanisms of action of drug candidates, statements concerning the goals and
timing
of seeking regulatory approval of our product candidates (including with respect
to telavancin statements regarding any expectation (i) that we will be able
to respond fully or adequately to FDA's requests using currently existing
clinical data, (ii) that the third-party manufacturer will successfully
address the cGMP issues the FDA has noted, (iii) regarding the outcome of the
review of the telavancin NDA by the FDA's Anti-Infective Drugs Advisory
Committee and (iv) any expectation that the FDA will approve the telavancin
NDA on the basis of existing preclinical and clinical data or at all), the
enablingcapabilities of Theravance's approach to drug discovery and its
proprietaryinsights, statements concerning expectations for product candidates
throughdevelopment and commercialization and projections of revenue and other
financial items. These statements are based on the current estimates and
assumptions of the management of Theravance as of the date of the
presentation and are subject to risks, uncertainties, changes in
circumstances, assumptions and other factors that may cause the actual results
of Theravance to be materially different from those reflected in its
forward-looking statements. Important factors that could cause actual results to
differ materially from those indicated by such forward-looking statements
include, among
others, the potential that results of clinical or preclinical studies
indicate product candidates are unsafe, ineffective, inferior or not superior,
and
delays or failure to achieve regulatory approvals, risks of collaborating with
third
parties to develop and commercialize products and risks of relying on
third-party manufacturers for the supply of our product candidates. These and
other
risks are described in greater detail under the heading "Risk Factors"
contained in Item 1A of Theravance's Quarterly Report on Form 10-Q filed
with the Securities and Exchange Commission (SEC) on November 7, 2007 and the
risksdiscussed in our other filings with the SEC. Given these uncertainties,
youshould not place undue reliance on these forward-looking statements.
Theravance
assumes no obligation to update its forward-looking statements.

Contact Information:
Theravance, Inc.
Allison Parker
Director, Investor Relations
650-808-4100
Email Contact

Copyright 2008, Market Wire, All rights reserved.

-0-